vs
Side-by-side financial comparison of APTARGROUP, INC. (ATR) and IDEX Corporation (IEX). Click either name above to swap in a different company.
APTARGROUP, INC. is the larger business by last-quarter revenue ($962.7M vs $398.4M, roughly 2.4× IDEX Corporation). IDEX Corporation runs the higher net margin — 30.1% vs 7.7%, a 22.4% gap on every dollar of revenue. On growth, IDEX Corporation posted the faster year-over-year revenue change (16.7% vs 13.5%). APTARGROUP, INC. produced more free cash flow last quarter ($96.9M vs $86.0M). Over the past eight quarters, APTARGROUP, INC.'s revenue compounded faster (2.6% CAGR vs -29.4%).
AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.
IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.
ATR vs IEX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $962.7M | $398.4M |
| Net Profit | $74.3M | $120.0M |
| Gross Margin | — | 99.9% |
| Operating Margin | 11.0% | 43.3% |
| Net Margin | 7.7% | 30.1% |
| Revenue YoY | 13.5% | 16.7% |
| Net Profit YoY | -26.4% | 25.7% |
| EPS (diluted) | $1.13 | $1.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | — | $398.4M | ||
| Q1 26 | — | $407.7M | ||
| Q4 25 | $962.7M | $899.1M | ||
| Q3 25 | $961.1M | $878.7M | ||
| Q2 25 | $966.0M | $865.4M | ||
| Q1 25 | $887.3M | $814.3M | ||
| Q4 24 | $848.1M | $862.9M | ||
| Q3 24 | $909.3M | $798.2M |
| Q2 26 | — | $120.0M | ||
| Q1 26 | — | $128.3M | ||
| Q4 25 | $74.3M | $128.3M | ||
| Q3 25 | $127.9M | $127.8M | ||
| Q2 25 | $111.7M | $131.6M | ||
| Q1 25 | $78.8M | $95.5M | ||
| Q4 24 | $100.9M | $123.2M | ||
| Q3 24 | $100.0M | $119.1M |
| Q2 26 | — | 99.9% | ||
| Q1 26 | — | 94.9% | ||
| Q4 25 | — | 43.1% | ||
| Q3 25 | — | 44.5% | ||
| Q2 25 | — | 45.3% | ||
| Q1 25 | — | 45.3% | ||
| Q4 24 | — | 42.5% | ||
| Q3 24 | — | 44.3% |
| Q2 26 | — | 43.3% | ||
| Q1 26 | — | 45.0% | ||
| Q4 25 | 11.0% | 20.4% | ||
| Q3 25 | 14.2% | 21.1% | ||
| Q2 25 | 14.9% | 21.7% | ||
| Q1 25 | 12.8% | 17.4% | ||
| Q4 24 | 14.2% | 19.2% | ||
| Q3 24 | 15.2% | 21.0% |
| Q2 26 | — | 30.1% | ||
| Q1 26 | — | 31.5% | ||
| Q4 25 | 7.7% | 14.3% | ||
| Q3 25 | 13.3% | 14.5% | ||
| Q2 25 | 11.6% | 15.2% | ||
| Q1 25 | 8.9% | 11.7% | ||
| Q4 24 | 11.9% | 14.3% | ||
| Q3 24 | 11.0% | 14.9% |
| Q2 26 | — | $1.61 | ||
| Q1 26 | — | $1.71 | ||
| Q4 25 | $1.13 | $1.71 | ||
| Q3 25 | $1.92 | $1.70 | ||
| Q2 25 | $1.67 | $1.74 | ||
| Q1 25 | $1.17 | $1.26 | ||
| Q4 24 | $1.48 | $1.61 | ||
| Q3 24 | $1.48 | $1.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $409.5M | $586.2M |
| Total DebtLower is stronger | $1.1B | — |
| Stockholders' EquityBook value | $2.7B | $4.0B |
| Total Assets | $5.3B | $6.9B |
| Debt / EquityLower = less leverage | 0.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $586.2M | ||
| Q1 26 | — | $580.0M | ||
| Q4 25 | $409.5M | $580.0M | ||
| Q3 25 | $264.8M | $593.8M | ||
| Q2 25 | $169.8M | $568.2M | ||
| Q1 25 | $136.8M | $594.1M | ||
| Q4 24 | $226.2M | $620.8M | ||
| Q3 24 | $327.9M | $633.2M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $1.8B | ||
| Q3 25 | $546.0M | $1.9B | ||
| Q2 25 | $535.1M | $1.9B | ||
| Q1 25 | $561.2M | $2.0B | ||
| Q4 24 | $688.1M | $2.0B | ||
| Q3 24 | $822.7M | $2.1B |
| Q2 26 | — | $4.0B | ||
| Q1 26 | — | $4.0B | ||
| Q4 25 | $2.7B | $4.0B | ||
| Q3 25 | $2.8B | $4.0B | ||
| Q2 25 | $2.7B | $4.0B | ||
| Q1 25 | $2.5B | $3.9B | ||
| Q4 24 | $2.5B | $3.8B | ||
| Q3 24 | $2.5B | $3.8B |
| Q2 26 | — | $6.9B | ||
| Q1 26 | — | $6.9B | ||
| Q4 25 | $5.3B | $6.9B | ||
| Q3 25 | $5.1B | $7.0B | ||
| Q2 25 | $4.9B | $6.9B | ||
| Q1 25 | $4.5B | $6.8B | ||
| Q4 24 | $4.4B | $6.7B | ||
| Q3 24 | $4.6B | $7.0B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.43× | 0.45× | ||
| Q3 25 | 0.20× | 0.48× | ||
| Q2 25 | 0.20× | 0.46× | ||
| Q1 25 | 0.22× | 0.50× | ||
| Q4 24 | 0.28× | 0.52× | ||
| Q3 24 | 0.32× | 0.55× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.7M | — |
| Free Cash FlowOCF − Capex | $96.9M | $86.0M |
| FCF MarginFCF / Revenue | 10.1% | 21.6% |
| Capex IntensityCapex / Revenue | 9.0% | 4.4% |
| Cash ConversionOCF / Net Profit | 2.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $299.6M | $654.3M |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $183.7M | $209.5M | ||
| Q3 25 | $177.6M | $203.5M | ||
| Q2 25 | $126.0M | $161.7M | ||
| Q1 25 | $82.7M | $105.7M | ||
| Q4 24 | $178.2M | $172.6M | ||
| Q3 24 | $229.3M | $205.3M |
| Q2 26 | — | $86.0M | ||
| Q1 26 | — | $189.8M | ||
| Q4 25 | $96.9M | $189.8M | ||
| Q3 25 | $114.3M | $188.7M | ||
| Q2 25 | $62.5M | $146.9M | ||
| Q1 25 | $25.9M | $91.4M | ||
| Q4 24 | $112.2M | $157.1M | ||
| Q3 24 | $162.7M | $191.6M |
| Q2 26 | — | 21.6% | ||
| Q1 26 | — | 46.6% | ||
| Q4 25 | 10.1% | 21.1% | ||
| Q3 25 | 11.9% | 21.5% | ||
| Q2 25 | 6.5% | 17.0% | ||
| Q1 25 | 2.9% | 11.2% | ||
| Q4 24 | 13.2% | 18.2% | ||
| Q3 24 | 17.9% | 24.0% |
| Q2 26 | — | 4.4% | ||
| Q1 26 | — | 15.6% | ||
| Q4 25 | 9.0% | 2.2% | ||
| Q3 25 | 6.6% | 1.7% | ||
| Q2 25 | 6.6% | 1.7% | ||
| Q1 25 | 6.4% | 1.8% | ||
| Q4 24 | 7.8% | 1.8% | ||
| Q3 24 | 7.3% | 1.7% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 2.47× | 1.63× | ||
| Q3 25 | 1.39× | 1.59× | ||
| Q2 25 | 1.13× | 1.23× | ||
| Q1 25 | 1.05× | 1.11× | ||
| Q4 24 | 1.77× | 1.40× | ||
| Q3 24 | 2.29× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
IEX
Segment breakdown not available.
